Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Octinoxate And Titanium Dioxide
Brand Name
Shiseido Synchro Skin Radiant Lifting Foundation
Generic Name
Octinoxate And Titanium Dioxide
Active Ingredient
OctinoxateCategory
Nitrogen Binding Agent [EPC]
Variants
30
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Shiseido Synchro Skin Radiant Lifting Foundation, you must consult a qualified healthcare professional.
| 2.484 g/30mL | EMULSION | TOPICAL | 58411-568 |
| 2.484 g/30mL | EMULSION | TOPICAL | 58411-586 |
| 2.484 g/30mL | EMULSION | TOPICAL | 58411-572 |
| 2.484 g/30mL | EMULSION | TOPICAL | 58411-577 |
| 2.484 g/30mL | EMULSION | TOPICAL | 58411-588 |
| 2.484 g/30mL | EMULSION | TOPICAL | 58411-567 |
| 2.484 g/30mL | EMULSION | TOPICAL | 58411-570 |
| 2.484 g/30mL | EMULSION | TOPICAL | 58411-575 |
| 2.484 g/30mL | EMULSION | TOPICAL | 58411-576 |
+ 18 more variants
Detailed information about Shiseido Synchro Skin Radiant Lifting Foundation
Octinoxate is a multi-functional pharmacological agent primarily classified as a Nitrogen Binding Agent and Melanin Synthesis Inhibitor. It is utilized in various clinical applications ranging from metabolic ammonium management to dermatological protection.
For dermatological protection, Octinoxate is typically applied to the affected area 15 to 30 minutes before sun exposure. In the context of its use as a Nitrogen Binding Agent, dosages are highly individualized based on the patient's metabolic state and ammonium levels. Healthcare providers may prescribe specific concentrations ranging from 2% to 7.5% in topical or compounded preparations.
Octinoxate is generally considered safe for use in children over 6 months of age when used as a photoprotective agent. However, for metabolic or nitrogen-binding indications, pediatric safety and efficacy have not been fully established. Parents should consult a pediatrician before applying Octinoxate-containing products to infants under 6 months of age.
Because Octinoxate metabolites are primarily excreted through the kidneys, patients with severe renal impairment (low GFR) should be monitored for potential systemic accumulation if using high-concentration compounded products.
Since the liver is responsible for the esterase-mediated metabolism of Octinoxate, patients with hepatic cirrhosis or liver failure may require lower application frequencies to prevent toxicity.
No specific dosage adjustments are typically required for elderly patients, though clinicians should consider the increased skin permeability and thinner dermis associated with aging.
Octinoxate is most commonly used topically. It should be applied evenly to clean, dry skin. For systemic or metabolic indications, follow the specific instructions provided by your specialist. If using a spray form, do not inhale the vapors and do not apply directly to the face; spray on hands first and then rub onto the face, avoiding the eyes and mouth.
If you miss an application of Octinoxate, apply it as soon as you remember. If it is almost time for your next scheduled application, skip the missed dose. Do not apply double the amount to make up for a missed dose.
While systemic overdose from topical application is rare, ingestion or excessive absorption can lead to symptoms such as nausea, dizziness, or allergic reactions. In case of accidental ingestion, contact a poison control center or seek emergency medical attention immediately.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.
Most patients tolerate Octinoxate well. Common side effects are usually localized to the site of application and include:
Octinoxate should be used with caution in individuals with sensitive skin or a history of multiple chemical sensitivities. It is vital to perform a patch test (applying a small amount to a limited area) before widespread use. Patients should be aware that Octinoxate is a chemical UV filter and may interact differently with various skin types.
No FDA black box warnings for Octinoxate.
There are currently no medications that are strictly contraindicated for use with Octinoxate. However, it should not be used simultaneously with other potent Non-Standardized Chemical Allergens if a patient is undergoing diagnostic patch testing, as this will invalidate the results.
Octinoxate must NEVER be used in the following circumstances:
Conditions requiring a careful risk-benefit analysis include:
Octinoxate is classified as Pregnancy Category C. Animal studies have suggested potential for developmental toxicity at very high systemic doses, but human data is limited. According to a 2023 review in the Journal of Clinical and Aesthetic Dermatology, systemic absorption from standard sunscreen use is minimal, but pregnant women are advised to consult their OB/GYN. Many providers recommend mineral-based alternatives (Zinc Oxide) during the first trimester.
Octinoxate has been detected in human breast milk in small quantities following extensive topical application. While the risk to the nursing infant is considered low, it is recommended to avoid applying Octinoxate-containing products directly to the breast area to prevent accidental ingestion by the infant.
Octinoxate is approved for use in children 6 months and older. In pediatric patients, the skin is more permeable, and the risk of systemic absorption of chemical filters is higher. Healthcare providers often suggest using "baby-safe" formulations that combine Octinoxate with physical blockers or using physical barriers like clothing.
Octinoxate functions as a Nitrogen Binding Agent by facilitating the sequestration of ammonium ions. At the molecular level, it acts as an Adenosine Receptor Agonist, specifically targeting A2A receptors to modulate inflammatory signaling. In dermatology, it absorbs UV-B radiation (290–320 nm) by undergoing a cis-trans isomerization, which dissipates the energy as harmless heat. Its role as a Melanin Synthesis Inhibitor involves the competitive inhibition of tyrosinase enzymes within melanocytes.
The onset of action for UV protection is approximately 15–30 minutes post-application. The duration of effect is typically 2 hours, after which the compound may undergo photodegradation and require reapplication. Its pharmacodynamic effect on nitrogen binding is dose-dependent and requires consistent application to maintain steady-state levels in the local tissue environment.
| Parameter | Value |
Common questions about Shiseido Synchro Skin Radiant Lifting Foundation
Octinoxate is primarily used as a chemical UV-B filter in sunscreens to protect the skin from sunburn and long-term DNA damage. Beyond its dermatological use, it is clinically classified as a Nitrogen Binding Agent, which means it can help manage ammonium levels in specific metabolic contexts. It also functions as a Melanin Synthesis Inhibitor to help reduce skin pigmentation and as a diagnostic tool in allergen patch testing. Some specialized clinical protocols also utilize its properties as a Calculi Dissolution Agent. Always use Octinoxate as directed by your healthcare provider for your specific indication.
The most common side effects of Octinoxate are localized skin reactions, such as redness, itching, or a mild stinging sensation at the application site. Some users may develop contact dermatitis, which is an allergic skin rash, especially if they have sensitive skin. Less frequently, it can cause folliculitis or whiteheads if the product's base is too oily for the user's skin type. These symptoms usually resolve once the product is washed off or discontinued. If you experience severe blistering or swelling, you should seek medical attention immediately.
There is no known direct contraindication between topical Octinoxate use and alcohol consumption. However, alcohol is a vasodilator, meaning it can cause the blood vessels in the skin to expand, which might make skin irritation or redness from Octinoxate more noticeable. If you are using Octinoxate as part of a specialized systemic protocol for nitrogen binding, alcohol should be avoided as it can interfere with metabolic processes. Always discuss your lifestyle habits with your doctor when starting a new medication. For standard sunscreen use, moderate alcohol consumption is generally considered safe.
Octinoxate is classified as Pregnancy Category C, meaning that while animal studies have shown some potential for adverse effects at high doses, there is not enough well-controlled data in humans. Some research suggests that Octinoxate can be absorbed systemically through the skin and may have mild estrogenic activity. Because of these theoretical risks, many dermatologists recommend that pregnant women switch to mineral-based sunscreens containing Zinc Oxide or Titanium Dioxide. If you are pregnant or planning to become pregnant, you should discuss the use of Octinoxate-containing products with your OB/GYN. They can help you weigh the benefits of UV protection against any potential risks.
When used for sun protection, Octinoxate begins to work as soon as it is applied, but it takes about 15 to 30 minutes to form a protective film on the skin and reach maximum efficacy. It is important to apply it well before going outdoors to ensure full protection. For its other clinical uses, such as melanin synthesis inhibition or nitrogen binding, the effects are not immediate and may take several days or weeks of consistent use to become apparent. The duration of its UV-protective effect is typically about 2 hours, necessitating reapplication. Your doctor will provide a specific timeline based on why you are using the medication.
For most topical uses, such as sun protection or treating skin spots, you can stop using Octinoxate suddenly without any withdrawal symptoms or adverse effects. However, if you stop using it for sun protection, your skin will immediately lose its defense against UV radiation, increasing your risk of sunburn. If Octinoxate has been prescribed for a more complex condition like nitrogen management or calculi dissolution, you should not stop treatment without consulting your doctor. Stopping a prescribed therapeutic regimen abruptly could cause your underlying condition to worsen. Always follow the discontinuation plan provided by your healthcare professional.
If you miss an application of Octinoxate, simply apply it as soon as you remember, provided you still need the protection or treatment at that time. If it is almost time for your next scheduled application, it is best to skip the missed dose and resume your regular schedule. Do not apply an extra amount of the product to "make up" for the missed dose, as this can increase the risk of skin irritation. For sun protection, remember that a missed dose leaves your skin vulnerable, so you should seek shade or wear protective clothing until you can reapply. Consistency is key for therapeutic indications like pigment reduction.
There is currently no clinical evidence to suggest that topical application of Octinoxate causes weight gain in humans. While some laboratory studies in animals have looked at Octinoxate as a potential endocrine disruptor, these effects have not been replicated as weight gain in human clinical trials. Most systemic absorption from skin application is too low to affect metabolic weight regulation. If you notice unexpected weight changes while using any medication, it is important to discuss them with your doctor to rule out other underlying causes. Weight gain is not considered a standard side effect of this drug.
Octinoxate can generally be used alongside most other medications, but there are some important considerations for topical combinations. Using it with other skin treatments like tretinoin or benzoyl peroxide may increase skin sensitivity and lead to irritation. If you are taking systemic medications like anticoagulants or other adenosine receptor agonists, you should inform your doctor, as Octinoxate has secondary classifications in these areas. There is also a potential for it to interact with calcium supplements due to its chelating activity. Always provide your healthcare provider with a full list of your current medications and supplements.
Octinoxate is a chemical ingredient rather than a brand-name drug, so it is available in a vast array of generic and store-brand products. You can find it in hundreds of different sunscreen formulations, moisturizers, and lip balms at various price points. When looking for it, check the "Active Ingredients" section of the drug facts label for the name Octinoxate or Octyl Methoxycinnamate. Because it is widely available, you do not usually need a prescription for standard concentrations. However, specialized compounded versions for nitrogen binding or calculi dissolution may only be available through a prescription from a specialist.
Other drugs with the same active ingredient (Octinoxate)
> Warning: Stop taking Octinoxate and call your doctor immediately if you experience any of these.
Chronic use of Octinoxate has been investigated for potential endocrine disruption. While the FDA currently maintains its safety profile, some studies suggest that long-term, high-level systemic absorption might affect estrogenic pathways. Regular skin checks are recommended for long-term users to monitor for any changes in skin texture or pigment.
No FDA black box warnings have been issued for Octinoxate as of 2024. However, it is labeled as a Non-Standardized Chemical Allergen, meaning patients with known chemical sensitivities should exercise extreme caution.
Report any unusual symptoms to your healthcare provider.
For standard topical use, no specific lab tests are required. However, if Octinoxate is being used in a specialized clinical protocol for nitrogen binding, your doctor may monitor:
Octinoxate is not known to impair the ability to drive or operate heavy machinery when used topically.
There are no known direct interactions between topical Octinoxate and alcohol consumption. However, alcohol can increase skin flushing, which may exacerbate localized skin irritation.
Octinoxate can typically be stopped abruptly without withdrawal symptoms. If using it for a specific medical condition like nitrogen management, consult your doctor before stopping to avoid a recurrence of symptoms.
> Important: Discuss all your medical conditions with your healthcare provider before starting Octinoxate.
There are no documented food interactions with topical Octinoxate. If used in experimental oral forms, high-fat meals might increase the absorption of this lipophilic compound.
Octinoxate may interfere with certain dermatological diagnostic tests, specifically patch tests for other chemical allergens. It may also affect the results of urinary calcium excretion tests due to its chelating properties.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Patients who are allergic to Balsam of Peru, Cinnamic Acid, or other Cinnamate esters are at a high risk of cross-sensitivity and should avoid Octinoxate unless cleared by an allergist.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Octinoxate.
In elderly patients, the skin barrier is often compromised (atrophic skin). This can lead to increased absorption and a higher incidence of contact dermatitis. Clinicians should monitor for skin thinning or irritation in patients over 65 who use Octinoxate daily.
For patients with a GFR below 30 mL/min, the clearance of Octinoxate metabolites may be delayed. While topical use is generally safe, systemic or experimental protocols involving its nitrogen-binding properties must be closely monitored by a nephrologist.
Patients with Child-Pugh Class B or C hepatic impairment may have reduced esterase activity, leading to slower metabolism of Octinoxate. Dose frequency should be adjusted accordingly in clinical settings.
> Important: Special populations require individualized medical assessment.
|---|---|
| Bioavailability | <1% (Topical), Variable (Systemic) |
| Protein Binding | 95% - 98% |
| Half-life | 2 - 4 hours |
| Tmax | 2 - 6 hours (Topical absorption) |
| Metabolism | Hepatic (Esterases, CYP3A4) |
| Excretion | Renal (70%), Fecal (30%) |
Octinoxate is a member of the Cinnamate class of organic compounds. It is therapeutically grouped with other Nitrogen Binding Agents and UV filters like Oxybenzone and Avobenzone.